FDA Assails Amgen's Sensipar Exclusivity Suit
The U.S. Food and Drug Administration on Wednesday assailed a new lawsuit from Amgen Inc. challenging denied exclusivity for blockbuster calcium-control drug Sensipar, calling the suit premature and arguing that Amgen...To view the full article, register now.
Already a subscriber? Click here to view full article